IMAGE

FIGURE 6

ID
ZDB-IMAGE-231228-136
Source
Figures for Valencia-Sama et al., 2023
Image
Figure Caption

FIGURE 6

Alterations in RAS-MAPK pathway associate with lorlatinib resistance. A, Abundance of specific BRAF, RAF1, and ERK2 phospho-sites identified by LC/MS-MS in Kelly-LR samples relative to Kelly-S. B, GTP pulldown (PD) of WCE lysates of Kelly-S and Kelly-LR cells. IB, immunoblot. C, Western immunoblots of Kelly-S and Kelly-LR cells treated with TNO155 (1.5 µmol/L), lorlatinib (1 µmol/L) or combination treatment for 6 hours. *, P < 0.05; **, P < 0.01; n.s., not significant.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cancer Res Commun
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.